Dr. Dylan Dupuis is a biotechnology finance professional with experience spanning trading, portfolio management, and equity research. His scientific insights drive his approach to biotech analysis, paired with a deep, integrated view on stage-based risk and commercial value.

Dylan began his career as a trader and later branch manager at Seven Points Capital, where he helped the team achieve seven consecutive profitable quarters. He then moved into the world of biotech finance, first as a research associate at B. Riley FBR before joining and advancing to Vice President of Equity Research at SVB Leerink. In these roles, he helped launch or lead research coverage on nearly 50 SMID-cap biotech companies spanning immunology, metabolic disease, oncology, neurology, rare diseases, and regenerative medicine.

Following Leerink, he moved to Altium Capital, where he co-managed a roughly $100 million healthcare portfolio that outperformed the XBI over two years before moving to ROTH MKM as Managing Director and Senior Analyst to lead SMID-cap biotech coverage.

Dylan received his Bachelors of Science degree in Biology and Chemistry from Lycoming College and earned his PhD in Molecular Biology from Lehigh University. At Lehigh University, Dylan investigated the regulatory role of A-to-I RNA editing in non-protein-coding RNAs and showed that repetitive-element–derived RNAs undergo similar editing, independent of the RNA polymerase responsible for their transcription.

Subsequently, Dylan completed his Research Fellowship with William Aird at the Center for Vascular Biology Research (CVBR) at Beth Israel Deaconess Medical Center, Harvard Medical School. At CVBR, Dylan secured independent NIH funding and demonstrated the critical role of the PI3K/AKT/FOXO1 pathway in neovascular development. He later led preliminary studies of ERG-regulated lncRNAs, leveraging a stem-cell model of vascular development to demonstrate their influence on endothelial differentiation.